409 results match your criteria: "Japanese Red Cross Kyoto Daiichi Hospital.[Affiliation]"
Oncoimmunology
December 2025
Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan.
This retrospective, multicenter cohort study aimed to determine whether cancer cachexia serves as a biomarker for determining the most effective treatment for patients having non-small-cell lung cancer (NSCLC) with high programmed death ligand 1 (PD-L1) expression treated with immune checkpoint inhibitors (ICIs) alone or combined with chemotherapy (ICI/chemotherapy). We included 411 patients with advanced NSCLC with a PD-L1 tumor proportion score of ≥50%. The patients were treated with pembrolizumab monotherapy or ICI/chemotherapy.
View Article and Find Full Text PDFFront Psychiatry
November 2024
Department of Psychiatry (Psychosomatic Medicine), Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
Somatic symptom disorder (SSD) is characterized by persistent physical symptoms that cause significant distress and functional impairment. Despite the widespread use of serotonin reuptake inhibitors (SRIs) in treating SSD, some patients experience insufficient response, necessitating alternative therapeutic approaches. We report two cases of SSD that demonstrated significant improvement with vortioxetine, a novel antidepressant with multimodal serotonergic receptor activity.
View Article and Find Full Text PDFRinsho Shinkeigaku
December 2024
Department of Neurology and Stroke Treatment, Japanese Red Cross Kyoto Daiichi Hospital.
We present a case of a 53-year-old man who was admitted with lower back pain and bilateral lower limb weakness. Neurologically, he exhibited paralysis of both lower limbs, complete sensory loss below the 10th thoracic spinal level, and bladder and rectal dysfunction. Spinal MRI revealed intramedullary high-signal lesions extending from the 10th vertebral level to the conus medullaris on diffusion-weighted and T-weighted images.
View Article and Find Full Text PDFInt J Urol
November 2024
Department of Urology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Kyoto, Japan.
Oncol Lett
January 2025
Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
Front Immunol
November 2024
Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Interstitial lung disease (ILD) is a serious complication of connective tissue diseases (CTDs). The heterogeneity of ILDs reflects differences in pathogenesis among diseases. This study aimed to clarify the characteristics of CTD-ILDs via a detailed analysis of the bronchoalveolar lavage fluid (BALF) and blood immune cells.
View Article and Find Full Text PDFRespir Med Case Rep
October 2024
Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
A 54-year-old woman with fever and cough presented with left upper lobe consolidation and para-aortic and hilar lymphadenopathies and was diagnosed with sarcoidosis, and her condition improved spontaneously. Over the next 15 years, the patient experienced seven similar episodes and was treated with glucocorticoids for the first time in the eighth episode, but subsequently died of respiratory failure. The autopsy revealed diffuse alveolar damage and co-infection with and Mucorales in the lungs and mediastinum.
View Article and Find Full Text PDFCancer Res Treat
October 2024
Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Cureus
September 2024
Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto, JPN.
Catheter Cardiovasc Interv
November 2024
Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Background: Despite the widespread use of drug-coated balloons (DCBs) for femoropopliteal (FP) lesions, there is still no consensus on treatment strategies for DCB restenosis. This study aimed to determine the risk factors for recurrent restenosis after repeat DCB therapy for DCB restenosis in FP lesions.
Methods: This multicenter retrospective study assessed 1176 consecutive limbs in 860 patients who successfully received initial DCB therapy for FP lesions at four cardiovascular centers between May 2018 and December 2022.
Transl Lung Cancer Res
August 2024
Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Background: Tumor markers such as serum carcinoembryonic antigen (CEA) and cytokeratin fragment 19 (CYFRA 21-1) are utilized for assessing the effectiveness of chemotherapy in non-small cell lung cancer (NSCLC) patients. Yet, it remains uncertain whether these markers can reliably forecast responses to combined chemoimmunotherapy. Our study aimed to examine the significance and effectiveness of these markers in predicting responses among NSCLC patients undergoing combined chemoimmunotherapy.
View Article and Find Full Text PDFAnn Gastroenterol Surg
September 2024
Second Department of Surgery Wakayama Medical University, School of Medicine Wakayama Japan.
Liver Int
November 2024
Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
Invest New Drugs
October 2024
Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo, 180-8610, Japan.
Anticancer Res
September 2024
Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan;
Background/aim: Maintaining liver function throughout the treatment of hepatocellular carcinoma (HCC) is crucial, yet the impact of durvalumab plus tremelimumab (DT) treatment on liver function is not well understood. This multicenter study aimed to examine the changes in liver function during DT treatment.
Patients And Methods: This nationwide multicenter study included 80 patients who received DT treatment for unresectable HCC.
Invest New Drugs
October 2024
Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan.
The association between depth of response (DpR) and treatment outcomes has been documented across various types of cancer. Immune checkpoint inhibitor (ICI)-based treatment is globally used as first-line treatment for non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1) expression ≥ 50%. However, in this population, the significance of DpR is not elucidated.
View Article and Find Full Text PDFIn ALK-negative anaplastic large cell lymphoma (ALCL), gene rearrangements of and are considered mutually exclusive. The former predicts a favorable prognosis, while the latter is generally unfavorable. We report the first case of ALK-negative ALCL in a leukemic phase with small cell pattern transformation, harboring double-hit rearrangements of the gene by inv(6)(p25q21) and gene by TBL1XR1-TP63 inversion.
View Article and Find Full Text PDFPhys Med
September 2024
Department of Radiology, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Purpose: We aimed to predict the neurological prognosis of cardiac arrest (CA) patients using quantitative imaging biomarkers extracted from brain computed tomography images.
Methods: We retrospectively enrolled 86 CA patients (good prognosis, 32; poor prognosis, 54) who were treated at three hospitals between 2017 and 2019. We then extracted 1131 quantitative imaging biomarkers from whole-brain and local volumes of interest in the computed tomography images of the patients.
Thromb J
August 2024
Department of Hematology and Blood Transfusion Medicine, Nara Medical University Hospital, 840 Shijyo-Cho, Kashihara, Nara, 634-8522, Japan.
Thorac Cancer
September 2024
Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Background: Advances in anticancer drugs for lung cancer (LC) have improved the prognosis of LC. Chronic pulmonary aspergillosis (CPA) is a progressive and often exacerbating respiratory disease with a poor prognosis. To date, the prognosis of LC complicated by CPA has not been elucidated.
View Article and Find Full Text PDFFront Immunol
July 2024
Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan.
Introduction: Several studies explored the association between thyroid transcription factor-1 (TTF-1) and the therapeutic efficacy of immunotherapy. However, the effect of TTF-1 on the therapeutic efficacy of programmed death-1 (PD-1) inhibitor/chemoimmunotherapy in patients with non-squamous non-small cell lung cancer (non-Sq NSCLC) with a programmed death-ligand 1 (PD-L1) tumor proportion score of 50% or more who are highly susceptible to immunotherapy remains unresolved. Therefore, we evaluated whether TTF-1 has a clinical impact on this population.
View Article and Find Full Text PDFJ Vasc Surg
December 2024
Department of Cardiology, Tokeidai Memorial Hospital, Sapporo, Japan.
Int J Hematol
September 2024
Department of Laboratory Medicine, Aiseikai Yamashina Hospital, Kyoto, Japan.
Cureus
June 2024
Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, JPN.
We report two patients who were treated with remdesivir, steroids, and tocilizumab for severe coronavirus disease 2019 (COVID-19) and developed lung abscesses and pleuritis. Although complications due to bacterial infections are often reported in COVID-19 patients, these severe infections are rare. Patients receiving tocilizumab are at a high risk of developing serious bacterial infections, and the diagnosis is often delayed because symptoms such as fever and elevated C-reactive protein levels are often minimal.
View Article and Find Full Text PDF